论文部分内容阅读
目的探讨宫腔镜电切术联合米非司酮治疗黏膜下Ⅱ型子宫肌瘤的临床疗效和安全性。方法随机将2010年5月至2012年5月住院治疗的128例黏膜下Ⅱ型子宫肌瘤患者分为A组和B组,每组各64例。A组给予宫腔镜电切术治疗,而B组患者则在宫腔镜电切术治疗治疗前给予米非司酮,比较两组患者临床疗效和药物不良反应。结果 B组患者治疗满意率(96.9%)明显高于A组患者(84.4%),两组患者未见明显不良反应(P>0.05)。结论宫腔镜电切术联合米非司酮治疗黏膜下Ⅱ型子宫肌瘤临床疗效确切,不良反应少,安全可靠,值得进一步推广。
Objective To investigate the clinical efficacy and safety of hysteroscopic electrotomy combined with mifepristone in the treatment of submucosal type Ⅱ uterine fibroids. Methods A total of 128 patients with submucosal type Ⅱ uterine fibroids hospitalized from May 2010 to May 2012 were randomly divided into A group and B group, with 64 cases in each group. Group A received hysteroscopic resection, while Group B received mifepristone before hysteroscopic resection. The clinical efficacy and adverse drug reactions were compared between the two groups. Results The satisfaction rate of treatment in group B (96.9%) was significantly higher than that in group A (84.4%). There was no obvious adverse reaction in both groups (P> 0.05). Conclusion Hysteroscopic resection combined with mifepristone treatment of submucosal type Ⅱ uterine fibroids clinical curative effect, less adverse reactions, safe and reliable, it is worth further promotion.